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Abstract
After several decades during which children tended to be excluded from clinical trials, 
provisions to encourage trials with children have been in place for some years both at 
international level and in individual countries. The Nuffield Council on Bioethics has 
published a broad-ranging report on the subject, which makes concrete proposals for 
decision-makers and comes at a crucial moment in the definition of European Union 
regulations on this topic.
For some years now, attempts have been made to re-
verse the tendency to exclude minors from taking part 
in clinical trials, with many nations adopting legislation. 
The European Union, for example, adopted a Regula-
tion on the matter in 2006 [1, 2]. 
The exclusion of minors sprang from the albeit com-
mendable intention of protecting particularly vulner-
able individuals from possible risks, but has proved to 
be a serious obstacle to the development of drugs for 
use specifically in paediatrics. In other words, the inten-
tion of protecting minors from the risks deriving from 
trials has excluded those same minors from the possible 
benefits to be gained from such research. This has led 
to the widespread use of off-label drugs in paediatrics 
in both primary and hospital care [3]. A large study 
in Sweden found that approximately 70% of all drugs 
given to neonates in hospital care were off-label, non-
approved drugs or drugs insufficiently documented for 
the specific age group [4].
Several institutions have published extensive refer-
ence papers and guidelines regarding the scientific and 
ethical principles involved in the conduct of clinical tri-
als with children, two examples being the US Institute 
of Medicine’s “The ethical conduct of clinical research 
involving children” [5] and the British Medical Research 
Council’s “Medical research involving children” [6].
Such documents usual agree that paediatric trials 
should be allowed only when certain requisites are satis-
fied. More specifically, trials may be acceptable: if they 
are directly associated with a clinical condition affect-
ing the interested minor, are of such a nature that they 
can be conducted only with minors and not with legally 
competent persons, and are conducted in full compli-
ance with the principle of the child’s best interest; if 
they are intended to study treatments for a clinical con-
dition that affects only minors, or are necessary to con-
validate in minors findings obtained in clinical trials in-
volving subjects able to provide informed consent; if the 
benefit to the interested minor is greater than the as-
sociated risks or burdens; if, where the aim is to achieve 
a benefit for the population that the minor represents, 
the risk for the interested minor is minimum in rela-
tion to the standard treatment adopted for his or her 
condition; if informed consent has been obtained from 
the person(s) having parental responsibility or from the 
legally appointed representative; if a minor who has 
reached an adequate level of intellectual capacity is ac-
tively involved in the informed consent procedure.
One of the more delicate aspects concerns the balance 
between the benefit to the individual and the scientific 
interest in acquiring new knowledge that may be useful 
for the treatment of future patients. Ethical documents 
agree that the former should take precedence over the 
latter, as the WMA’s Declaration of Helsinki clearly as-
serts: “While the primary purpose of medical research 
is to generate new knowledge, this goal can never take 
precedence over the rights and interests of individual re-
search subjects” (Article 8) [7]. The interpretation and 
application of this principle are nonetheless not without 
ambiguity, as attested by the fact that the “Report of the 
International Bioethics Committee of UNESCO (IBC) 
on consent” states in paragraph 87 that “Research ac-
tivities involving children are carried out to learn more 
about the nature of paediatric development, disease and 
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potential treatments. Though one might hope that it will 
in some cases be beneficial to the research participant, 
the activity cannot be said to be specifically designed 
for this purpose because of the nature of the research 
question” [8]. In this context it is worth mentioning 
the recent report by the Nuffield Council on Bioethics 
“Children and clinical research: ethical issues” [9]. The 
Nuffield Council on Bioethics is an independent body 
that examines and reports on ethical issues in biology 
and medicine and that has achieved an international 
reputation for advising policy makers. The report [9] 
was prepared by a working group set up in 2013 and is 
the product of consultations involving over 500 experts 
from around the globe. The final recommendations are 
concerned in particular with: the adoption of simple but 
efficacious regulations to facilitate paediatric research; 
the balance between parental consent and the assent of 
the minor; the promotion of transparency in procedures, 
also with a view to encouraging the exchange of scien-
tific information and data; the adoption of strategies 
that increase public awareness of the need for clinical 
trials. Rather than adding yet another checklist on the 
ethical acceptability of paediatric research, the Nuffield 
Council’s report is an attempt to submit a series of rec-
ommendations to the institutions concerned. Among its 
recommendations, for instance, are proposals: that the 
Royal College of Paediatrics and Child Health act to 
ensure that “outcomes of “innovative” or “experimental” 
treatment given to children and young people outside 
the context of research is properly documented”; that 
institutions “establish a database of experts”; that Par-
liament take appropriate measures to increase public 
awareness concerning paediatric trials; that the Euro-
pean Medicines Agency’s Paediatric Committee review 
the class waiver system that exempts certain categories 
of drugs from the requirement to include young people 
in clinical trials. 
The significance of the Nuffield Council’s recommen-
dations beyond the borders of the United Kingdom is 
due not only to their applicability in different contexts 
but also, in the case of EU Member States, to the cur-
rent situation in the European Union. On 16th June 
2014 “Regulation (EU) 536/2014 of the European Par-
liament and of the Council of 16th April 2014 on clinical 
trials on medicinal products for human use, and repeal-
ing Directive 2001/20/EC” [10] entered into force. This 
will become fully applicable after 29th May 2016 (but in 
any case not before a new single data base for all mem-
ber states, as provided for in the Recommendation, en-
ters into operation). This is thus a propitious moment 
for individual states, as well as the European Union as 
a whole, to adopt scientifically and ethically solid proce-
dures to encourage paediatric trials.
Conflict of interest statement
None to declare.
Accepted on 12 November 2015.
REFERENCES
1. European Parliament, Council of the European Union. 
Regulation (EC) No 1901/2006 of the European Parlia-
ment and of the Council of 12 December 2006 on medic-
inal products for paediatric use and amending Regulation 
(EEC) No 1768/92, Directive 2001/20/EC, Directive 
2001/83/EC and Regulation (EC) No 726/2004. Off J 
Eur Union 27 December 2006;L378:1-19.
2. European Parliament, Council of the European Union. 
Regulation (EC) No 1902/2006 of the European Parlia-
ment and of the Council of 20 December 2006 amending 
Regulation 1901/2006 on medicinal products for paediat-
ric use. Off J Eur Union 27 December 2006; L378:20-1.
3. Kimland E, Odlind V. Off-label drug use in pediatric pa-
tients. Clin Pharmacol Ther 2012;91(5):796-801.
4. Kimland E, Nydert P, Odlind V, Böttiger Y, Lindemalm S. 
Paediatric drug use with focus on off-label prescriptions 
at Swedish hospitals. A nationwide study. Acta Paediatr 
2012;101(7):772-8.
5. Institute of Medicine (US). Committee on Clinical Re-
search Involving Children, Board on Health Sciences 
Policy. Field MJ, Berman RE (Eds). The ethical conduct 
of clinical research involving children. Washington DC: Na-
tional Academies Press; 2004.
6. Medical Research Council. MRC ethics guide. Medical 
research involving children. 2004. Available from: www.
mrc.ac.uk/documents/pdf/medical-research-involving-
children.
7. World Medical Association. Declaration of Helsinki. 
Ethical Principles for Medical Research Involving Human 
Subjects. 1964-2013. Available from: www.wma.net/
en/30publications/10policies/b3.
8. United Nations Educational, Scientific and Cultural 
Organization (UNESCO). 2008. Report of the Interna-
tional Bioethics Committee of UNESCO (IBC) on Con-
sent. Available from: http://unesdoc.unesco.org/images/ 
0017/001781/178124e.pdf
9. Nuffield Council on Bioethics. Children and clinical re-
search: ethical issues. 2015. Available from: http://nuffield-
bioethics.org/wp-content/uploads/Children-and-clinical-
research-full-report.pdf
10. European Parliament, Council of the European Union. 
Regulation (EU) 536/2014 of the European Parliament 
and of the Council of 16 April 2014 on clinical trials on 
medicinal products for human use, and repealing Direc-
tive 2001/20/EC. Off J Eur Union 27 May 2014;L158:1-
76.
